The proposed research plan builds on our groups ongoing research to quantify ophthalmic and intracranial changes in long duration space flight astronauts using novel non-invasive magnetic resonance…

Ended Grant For Research Awarded Last action

Contract number
80NSSC22K0023
Awardee
Awarding agency
Obligated
$1,265,998

Award facts

Contract value 100% obligated
$1,265,998.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
Not on record
Set-aside
No set-aside
Competition
Full and Open Competition Basic Research
Pricing
Other
Place of performance
Lowell, MA 01852, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Funding Only Action P00016 · 18-18SANS_1-0028 ophthalmic and intracranial structural changes in head-down tilt bedrest: potential countermeasures and comparison to sans findings in… $65,998
Funding Only Action P00015 $50,000
Funding Only Action P00014 $150,000
Funding Only Action P00013 $100,000
Other Administrative Action P00012 $0
Funding Only Action P00011 $125,000
Funding Only Action P00010 $60,000
Funding Only Action P00009 $60,000
Funding Only Action P00008 $150,000
Additional Work (new agreement, FAR part 6 applies) P00007 · Ophthalmic and intracranial structural changes in head-down tilt bedrest: potential countermeasures and comparison to sans findings in astronauts(optics study). $100,000
Funding Only Action P00006 $175,000
Funding Only Action P00005 $25,000
Funding Only Action P00004 · Ophthalmic and intracranial structural changes in head-down tilt bedrest: potential countermeasures and comparison to sans findings in astronauts(optics study). $105,000
Funding Only Action P00003 $30,000
Funding Only Action P00002 $20,000
Other Administrative Action P00001 $0
Original award $50,000
Show all 17

About this award

Written by GovTribe AI ·

Alcyone Therapeutics Inc., a biotechnology company, has been awarded a $1,265,998.00 grant from the National Aeronautics and Space Administration (NASA) Shared Services Center to conduct research on quantifying ophthalmic and intracranial changes in long-duration space flight astronauts. The research plan builds on Alcyone's ongoing work and will utilize novel non-invasive magnetic resonance imaging (MRI) protocols and post-processing. This research grant, which does not have a set-aside designation, is set to be completed by December 7, 2025 and aligns with NASA's efforts to understand the physiological impacts of long-duration spaceflight.

Description

As the agency reported it.

The proposed research plan builds on our groups ongoing research to quantify ophthalmic and intracranial changes in long duration space flight astronauts using novel non-invasive magnetic resonance imaging (MRI) protocols and post-processing

Quick answers

Who was awarded contract 80NSSC22K0023?

80NSSC22K0023 was awarded to Alcyone Therapeutics Inc. by Shared Services Center (National Aeronautics and Space Administration) on December 8, 2021.

How much is contract 80NSSC22K0023 worth?

The government has obligated $1,265,998 on 80NSSC22K0023.

Was contract 80NSSC22K0023 competed?

The extent of competition for 80NSSC22K0023 was full and open competition.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login